| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 60687-0252-67 | 60687-0252 | Ondansetron | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 5, 2019 | In Use | |
| 13668-0711-91 | 13668-0711 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 16, 2025 | In Use | |
| 51991-0346-01 | 51991-0346 | Pomalidomide | Pomalidomide | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 28, 2025 | In Use | |
| 43066-0001-01 | 43066-0001 | docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb 19, 2018 | In Use | |
| 70121-2701-01 | 70121-2701 | Denosumab-mobz | Oziltus | 70.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Dec 23, 2025 | In Use | |
| 72374-0101-10 | 72374-0101 | Filgrastim-txid | NYPOZI | 300.0 ug/300ug | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Sep 23, 2025 | In Use | |
| 00591-0488-05 | 00591-0488 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Mar 14, 1996 | Dec 31, 2017 | In Use | |
| 68001-0422-37 | 68001-0422 | Decitabine | Decitabine | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct 21, 2019 | In Use | |
| 55154-7832-05 | 55154-7832 | Metoclopramide | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Jul 9, 2025 | In Use | |
| 13668-0711-57 | 13668-0711 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 16, 2025 | In Use | |
| 67457-0833-06 | 67457-0833 | Pegfilgrastim | Fulphila | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Jul 9, 2018 | May 31, 2026 | In Use |
| 50742-0484-01 | 50742-0484 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 1, 2022 | Apr 30, 2026 | In Use |
| 55111-0497-05 | 55111-0497 | capecitabine | capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Dec 10, 2020 | In Use | |
| 70518-3539-01 | 70518-3539 | PREDNISONE | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 22, 2025 | In Use | |
| 70518-3540-01 | 70518-3540 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 24, 2023 | Nov 9, 2024 | In Use |
| 70121-1452-01 | 70121-1452 | Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 4.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-Articular, Intralesional, Intramuscular, Intravenous, Soft Tissue | Aug 27, 2018 | In Use | |
| 00378-6921-91 | 00378-6921 | abiraterone acetate | Abiraterone Acetate | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Dec 14, 2020 | In Use | |
| 52959-0392-06 | 52959-0392 | Dexamethasone | Dexamethasone | 0.75 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 28, 1983 | In Use | |
| 43063-0426-60 | 43063-0426 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 28, 2013 | Aug 1, 2019 | In Use |
| 76075-0101-21 | 76075-0101 | Carfilzomib | Kyprolis | 60.0 mg/30mL | Chemotherapy | Proteasome Inhibitor | 20S | Intravenous | Oct 1, 2025 | In Use | |
| 70518-0307-00 | 70518-0307 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 10, 2017 | In Use | |
| 59212-0111-10 | 59212-0111 | Nilutamide | Nilandron | 150.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Jan 1, 2016 | Oct 25, 2018 | In Use |
| 00591-2435-15 | 00591-2435 | Isotretinoin | Isotretinoin | 30.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Apr 29, 2021 | In Use | |
| 00008-0100-01 | 00008-0100 | Inotuzumab Ozogamicin | Besponsa | 0.25 mg/mL | Immunotherapy | Drug Antibody Conjugate | CD22 | Intravenous | Aug 18, 2017 | In Use | |
| 60687-0252-46 | 60687-0252 | Ondansetron | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 5, 2019 | In Use |
Found 12159 results — Export these results
Home